Clinical trials: Venous
Venous Thromboembolism
RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
RE-COVERY is a large, multi-national, multi-center observational study based on new data collection. The study will enroll and characterize patients within 30 days of being diagnosed with an acute DVT and/or PE.
- Trial name
- NCT02596230
- Where
- 222 sites in United States, Argentina and 35 more
- Volunteers
- 7,797 people
- Sponsor
- Boehringer Ingelheim
Heart Failure, Pulmonary Hypertension
Rivet PVS Therapy in Group 2 PH-HFpEF
This clinical investigation is a prospective, multicenter, non-randomized, open-label, Early Feasibility Study to evaluate the safety, performance, and initial clinical efficacy of the Rivet PVS therapy in patients with…
- Trial name
- NCT05205265
- Testing
- Rivet Shunt
- Where
- 3 sites in United States
- Sponsor
- NXT Biomedical
Venous Leg Ulcer, Venous Stasis
SkinTE® in the Treatment of Venous Leg Wounds
This study is a prospective, multi-center, randomized controlled trial designed to collect patient outcome data on a commercially available human autologous homologous skin construct with SOC dressing compared to SOC dressings…
- Conditions
- Venous Leg Ulcer, Venous Stasis, Venous Stasis Ulcer
- Trial name
- NCT03881267
- Testing
- Human Autologous Homologous Skin Construct, Additional Outer Dressing Application, Fibracol Wound Dressing
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- PolarityTE
Atrial Fibrillation
Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®)
The purpose of this study is to compare the efficacy, safety and efficiency of CARTO® 3 system guided THERMOCOOL® catheter ablation and fluoroscopy guided Pulmonary Vein Ablation Catheter® (PVAC®) guided ablation for the…
- Trial name
- CLARITY-AF (NCT01116557)
- Testing
- Radiofrequency Ablation procedure
- Volunteers
- 79 people
- Sponsor
- Biosense Webster, Inc.
Lower Extremity Chronic Venous Ulcers
Assessment of the Safety and Efficacy of DERMASTREAM™ - ENZYSTREAM™ System for the Treatment of Chronic Venous Ulcers
The study objectives are to evaluate DermastreamTM - EnzystreamTM system safety, tolerability and efficacy, as a potent method for debridement of nonhealing lower extremity chronic venous ulcers patients.
- Trial name
- ENZ-DER-002-IL (NCT00485329)
- Testing
- Papain
- Where
- 3 sites in Israel
- Volunteers
- 48 people
- Sponsor
- EnzySurge
Macular Edema, Diabetic Macular Edema
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
To evaluate the safety and tolerability of LKA651 in patients with macular edema from diabetic macular edema (DME), neovascular age-related macular degeneration (AMD), or retinal vein occlusions (RVO)
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusions
- Trial name
- NCT02867735
- Testing
- LKA651
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Deep Vein Thrombosis, Fibrillation, Atrial
Odiparcil For The Prevention Of Venous Thromboembolism
Odiparcil is being studied to determine if it can prevent blood clots from forming after a total knee replacement and also to prove that odiparcil is safe.
- Conditions
- Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- NCT00244725
- Testing
- Odiparcil, Warfarin, Coumadin
- Where
- 101 sites in United States, Australia and 11 more
- Volunteers
- 961 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
The study drug, BAY59-7939, is a new drug currently being tested in the prevention of VTE. It directly inhibits factor Xa, a blood component in the pathway which leads to coagulation (clotting of blood cells).
- Trial name
- NCT00402467
- Testing
- Rivaroxaban (BAY59-7939), Rivaroxaban, (BAY59-7939), Enoxaparine
- Where
- 36 sites in United States, Canada
- Volunteers
- 613 people
- Sponsor
- Bayer
Type2 Diabetes, Type1diabetes
Accuracy Characterization Study
To demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring System (System) interstitial glucose results against venous glucose reference and capillary fingerstick using the Consensus Error Grid over the wear…
- Conditions
- Type2 Diabetes, Type1diabetes, Insulin Dependent Diabetes
- Trial name
- ACS (NCT01932944)
- Testing
- No treatment
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Abbott Diabetes Care
HepatoCellular Carcinoma, Portal Vein Tumor Thrombosis
Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
This is a phase I/II dose-escalation study of lipotecan based concurrent chemoradiotherapy in hepatocellular carcinoma with portal vein tumor thrombosis.
- Trial name
- NCT03035006
- Testing
- Lipotecan
- Where
- 4 sites in Taiwan
- Volunteers
- 1 people
- Sponsor
- Taiwan Liposome Company
Venous Leg Ulcer (VLU)
Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover
The purpose of this study is to determine how well our dHPT (Dehydrated Human Placental Tissue) Product and Standard of Care work when compared to Standard of Care alone in achieving complete closure of venous leg ulcers.
- Trial name
- EVOLVE (NCT07230340)
- Testing
- Amnion-Intermediate-Chorion, Standard of Care (SOC)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Cellution Biologics
Chronic Venous Insufficiency (CVI), Deep Vein Reflux
Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-US)
Prospective, non-randomized, multicenter pre-market early feasibility study (EFS) to evaluate subjects treated with the BlueLeaf System for the treatment of symptomatic chronic venous insufficiency (CVI) of the lower extremity
- Trial name
- INFINITE-US (NCT04225806)
- Testing
- BlueLeaf® Endovenous Valve Formation System (BlueLeaf System)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Intervene, Inc.
Malaria, Vivax
A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution
This study will investigate the effect of Tafenoquine (TQ) 150 mg tablet ageing (dissolution profiles) on human exposure of TQ comparing the relative bioavailability of TQ from tablets exhibiting different dissolution profiles in…
- Trial name
- NCT02751294
- Testing
- Tafenoquine Control, Tafenoquine dissolution profile X, Tafenoquine SIL
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Venous Leg Ulcer, Leg Ulcers Venous
Efficacy Study for Geko Device in VLU Patients
Eight weeks, comprised of four weeks Run-in Phase of Standard Care (SC) treatment followed by four weeks of treatment allocated by randomisation (Treatment Phase).
- Conditions
- Venous Leg Ulcer, Leg Ulcers Venous, Leg Ulcer, Wound Leg
- Trial name
- NCT03396731
- Testing
- geko™ medical device
- Where
- 23 sites in United Kingdom
- Volunteers
- 171 people
- Sponsor
- Firstkind Ltd
Embolism and Thrombosis, Embolism
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex…
- Conditions
- Embolism and Thrombosis, Embolism, Vascular Diseases, Warfarin
- Trial name
- MHSMayoWarf1 (NCT00830570)
- Testing
- CYP 2C9 and VKORC1 Testing for Warfarin
- Where
- United States
- Volunteers
- 1,635 people
- Sponsor
- Medco Health Solutions, Inc.
Paroxysmal Atrial Fibrillation
Evaluation of Ablation Index and VISITAG™ (ABI-173)
The purpose of this study is to assess the safety, acute and long term effectiveness, during standard RF ablation procedures while using Ablation Index and VISITAG™ software in combination with a Thermocool SmartTouch® (ST) or…
- Trial name
- VISTAX (NCT03062046)
- Testing
- RF ablation
- Where
- 17 sites in Austria, Belgium and 7 more
- Volunteers
- 340 people
- Sponsor
- Biosense Webster, Inc.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Venous Insufficiency
Compression Device Safety Study
To evaluate the safety of the Compression Device to subjects with venous insufficiency and oedema.
- Trial name
- NCT00732823
- Testing
- Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- ConvaTec Inc.
Venous Thromboembolism
Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)
This study was designed to assess the safety and efficacy of GW813893 in the prophylaxis of VTE following TKR and to provide evidence to enable the selection of the appropriate dose(s) and dose regimen of GW813893 for future…
- Trial name
- NCT00541320
- Testing
- GW813893
- Where
- 8 sites in United States
- Sponsor
- GlaxoSmithKline
Venous Insufficiency
Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency
Study to assess the efficacy and tolerability of Antistax® film-coated tablets in patients with chronic venous insufficiency (CVI, Clinical condition, Etiology, Anatomic location, Pathophysiology (CEAP) Classification: Clinical…
- Trial name
- NCT02191254
- Testing
- Antistax®
- Volunteers
- 245 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.